Edition:
United Kingdom

Fennec Pharmaceuticals Inc (FENC.OQ)

FENC.OQ on NASDAQ Stock Exchange Capital Market

6.05USD
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
$6.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,710
52-wk High
$14.85
52-wk Low
$5.87

Latest Key Developments (Source: Significant Developments)

Fennec provides business update and announces third quarter results
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Fennec Pharmaceuticals Inc ::FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.FENNEC PHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS WERE $24.5 MILLION AS OF SEPTEMBER 30, 2018.FENNEC PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.14.FENNEC PHARMACEUTICALS - BELIEVES CASH, CASH EQUIVALENTS ON HAND AS OF SEPT 30, 2018 WILL BE SUFFICIENT TO FUND PLANNED COMMERCIAL LAUNCH OF PEDMARKTM.FENNEC PHARMACEUTICALS - EXPECTS LAUNCH OF PEDMARKTM UPON TARGETED APPROVAL IN SECOND HALF OF 2019.  Full Article

Fennec Pharmaceuticals Receives Breakthrough Therapy Designation By FDA For Pedmark™
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Fennec Pharmaceuticals Inc ::FENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK™.FENNEC PHARMACEUTICALS INC - ‍FDA GRANTED PEDMARK BREAKTHROUGH THERAPY DESIGNATION FOR PREVENTION OF CISPLATIN-RELATED OTOTOXICITY.  Full Article

Fennec Says Phase 3 SIOPEL 6 Study Met Primary Endpoint
Monday, 26 Mar 2018 

March 26 (Reuters) - Fennec Pharmaceuticals Inc ::FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2017 FINANCIAL RESULTS.PHASE 3 SIOPEL 6 STUDY MET PRIMARY ENDPOINT.FENNEC - SIOPEL 6 STUDY SHOWED ADDITION OF STS SIGNIFICANTLY REDUCES INCIDENCE OF CISPLATIN-INDUCED HEARING LOSS WITHOUT EVIDENCE OF TUMOR PROTECTION.QTRLY ‍LOSS PER SHARE $0.15​.FENNEC - ‍BELIEVES CASH & CASH EQUIVALENTS ON HAND AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED COMMERCIAL LAUNCH OF PEDMARK (TM) IN H2 2019.  Full Article

Fennec Announces Pricing Of Public Offering
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Fennec Pharmaceuticals Inc ::FENNEC ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 2.35 MILLION COMMON SHARES PRICED AT $8.50PER SHARE.  Full Article

Fennec Pharmaceuticals Q3 loss per share $0.15‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Fennec Pharmaceuticals Inc :Fennec provides business update and reports third quarter 2017 results.Fennec Pharmaceuticals Inc - qtrly loss per share $0.15‍​.Fennec Pharmaceuticals Inc - cash and cash equivalents at Sept 30,2017, $9.7 million versus $3.9 million at Dec 31, 2016‍​.  Full Article

Fennec pharmaceuticals files for stock shelf of up to $90 mln
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Fennec Pharmaceuticals Inc ::Files for stock shelf of up to $90 million - SEC filing‍​.  Full Article

Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Fennec Pharmaceuticals Inc :Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark (sodium thiosulfate) presented at the 49th Congress of the international Society of Pediatric Oncology (SIOP) 2017 meeting.Fennec Pharmaceuticals Inc - ‍study met primary endpoint​.Fennec - ‍significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with standard risk hepatoblastoma​.Says ‍treatment was well tolerated and acute toxicity similar and expected between arms​.Fennec Pharmaceuticals Inc - ‍company plans to pursue regulatory approvals with FDA and EMA​.Fennec Pharmaceuticals Inc - co also reported top-line data for secondary endpoints EFS and OS, combination of CIS+STS was generally well tolerated‍​.  Full Article

No consensus analysis data available.